Pleural Mesothelioma in the Era of Immunotherapy.
Over the course of the last decade, immunotherapy has revolutionised the management of a great number of cancer types. The treatment of pleural mesothelioma, a rare and highly aggressive cancer, is also being transformed by immunotherapy. The recent combination of ipilimumab and nivolumab improved o...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 6 |
|---|---|
| Autores principales: | , , , |
| Formato: | algorithm review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
7/20/2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=165472873&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 165472873 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 7/20/2023 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 165472873 165472873 165472873 10.1177/11795549231178173 165472873 ppf: 1 ppct: 5 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Pleural Mesothelioma in the Era of Immunotherapy. aug: au: Chevallier, Mathieu Kim, Floryane Friedlaender, Alex Addeo, Alfredo affil: Department of Oncology, University Hospital Geneva, Geneva, Switzerland sug: subj: Mesothelioma Therapy Pleural Neoplasms Therapy Immunotherapy Ipilimumab Therapeutic Use Nivolumab Therapeutic Use Chemotherapy, Cancer Rare Diseases ab: Over the course of the last decade, immunotherapy has revolutionised the management of a great number of cancer types. The treatment of pleural mesothelioma, a rare and highly aggressive cancer, is also being transformed by immunotherapy. The recent combination of ipilimumab and nivolumab improved overall survival compared with platinum-based chemotherapy, irrespective of the histology, establishing immunotherapy as a front-line standard of care in advanced pleural mesothelioma. Yet, most patients do not derive long-term benefit from any of the available therapies, and we note a significant lack of predictive and prognostic biomarkers. After progressing on first-line therapy, patients have limited therapeutic options, and data are scarce about optimal sequencing. In this perspective, we discuss the current management of pleural mesothelioma, defining what we consider to be the therapeutic sequence based on performance status and tumour histology. We also highlight promising ongoing trials that could further shape the management of this rare disease. pubtype: Academic Journal doctype: algorithm review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|